Triple-negative breast cancers (TNBC), which constitute about 20% of all breast cancers, lack estrogen receptor (ER) and progesterone receptor (PR) expression and do not show gene amplification of the human epidermal growth factor receptor 2 (HER2) [25]. This evidence concerns the gene ESR1 and breast carcinoma.